Advances in Ginsenosides

Chen, Jen‐Tsung

doi:10.3390/biom10050681

Cited by 15 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another active ingredient is ginsenosides, which exert anti-inflammatory effects by regulating the balance between pro-inflammatory and anti-inflammatory cytokines. The negative regulation of pro-inflammatory cytokine expressions (tumor necrosis factor α, interleukin-1β, and interleukin-6) and enzyme expressions (inducible nitric oxide synthase and cyclooxygenase-2) was identified as the anti-inflammatory mechanism of ginsenosides in M1-polarized macrophages and microglia ( Kim et al, 2017 ; Chen, 2020 ). The strong immuno-suppressive effects of ginsenoside Rg6 on Toll-like receptor 4–induced systemic inflammatory responses, such as liposaccharide-induced septic shock and cecal ligation and puncture-induced sepsis ( Paik et al, 2019 ), should be mentioned.…”

Section: Discussionmentioning

confidence: 99%

Effects of combination therapy with Shenfu Injection in critically ill patients with septic shock receiving mechanical ventilation: A multicentric, real-world study

Huang²,

Zhu³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Septic shock has increasingly become a cause of death threatening human survival. Shenfu Injection (SFI), a patented Chinese medicine, has been widely used in the treatment of patients with sepsis and cardiovascular diseases domestically. We sought to examine whether combination therapy with SFI can improve clinical outcomes in critically ill patients undergoing mechanical ventilation (MV).Methods: This real-world, multicenter retrospective trial enrolled consecutive adult patients with sepsis requiring MV from four medical/surgical intensive care units (ICUs) in China between August 2016 and September 2021. Patients were identified from the medical information department database of each center and assigned to either of two groups (SFI or control) on the basis of the initial treatment received. The primary outcome was 28-day all-cause mortality, and the durations of vasopressor therapy and MV, the ICU length of stay, and costs were assessed as secondary outcomes. Subsequently, we performed a meta-analysis of randomized controlled trials (RCTs) on SFI published before July 2021 to verify our conclusions.Results: 2311 mechanically ventilated patients with septic shock (1128 patients in the SFI group and 1183 in the control group) were analyzed. The survival probability during the first 28 days after admission in the SFI group was greater than that in the control group [p < 0.01 by log-rank test; hazard ratio (HR), 0.56; 95% confidence interval (CI), 0.39–0.72]. Patients in the SFI group also experienced a significantly reduced duration of vasopressor therapy [7.28 (95% CI, 6.14–8.42) vs. 12.06 (95% CI, 10.71–13.41) days, p < 0.001], more ventilator-free days [6.49 (95% CI, 5.42–7.55) vs. 10.84 (95% CI, 9.59–12.09) days, p < 0.001], a shorter ICU length of stay [18.48 (95% CI, 17.59–19.38) vs. 23.77 (95% CI, 22.47–25.07) days, p < 0.001], and more time free from organ failure [14.23 (95% CI, 12.94–15.52) vs. 19.07 (95% CI, 16.09–22.05) days, p < 0.001]. No major adverse effects were reported in either group.Conclusion: Among critically ill patients requiring MV, combination therapy with SFI can improve the survival probability without any obvious adverse reactions.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of combination therapy with Shenfu Injection in critically ill patients with septic shock receiving mechanical ventilation: A multicentric, real-world study

Huang²,

Zhu³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Ginsenoside, the main active ingredient of ginseng (Chen, 2020), has been proven to have a variety of pharmacological effects such as antiaging (Wan et al, 2020), promoting vascular development (Lee & Kim, 2014), and antitumor (Qu et al, 2021). It is the star product of Chinese herbal medicine.…”

Section: Ginsenosidesmentioning

confidence: 99%

Natural bioactive compounds as potential sources for alleviation and treatment of androgenetic alopecia: A research advance

Fang,

Yang,

Hui

et al. 2024

eFood

View full text Add to dashboard Cite

Alopecia is a common chronic skin disease, which can be categorized as androgenetic alopecia (AGA), scarring line alopecia, genetic alopecia, and chemical alopecia due to the different reasons. Among which AGA caused by metabolism of the androgen system accounts for the majority. Due to the high prevalence of AGA and the lack of an effective cure, the urgent search for a safe and effective anti‐AGA drug has been our aim. With the advantages of its own wide source and low toxicity and side effects, the use of natural bioactive compounds and their extracts in the treatment of AGA has been a research hotspot. The objective of this work is to compile and synthesize experimental findings on natural bioactive compounds that possess the potential to alleviate AGA. On the basis of the known pathogenesis of AGA, combined with the target analysis of AGA by network pharmacology, identify natural bioactive compounds and their signaling pathways for the treatment of alopecia and hair growth promotion, and select representative hotspot compounds, to reveal their specific mechanisms and abstract the commonalities. Based on previous extensive research, hundreds of AGA targets (e.g., Wnt, TGF, and VEGF) closely regulate neogenesis, tissue development, and vascular function, to collect and summarize compounds such as ginseng, baicalein, curcumin, and so on, which have great potential to improve hair growth. Our work will inspire future research based on their mechanisms of action, providing more complete evidence and ideas for the feasibility of developing natural anti‐AGA drugs.

show abstract

“…RES and PPD are plant polyphenols and ginseng extracts, respectively, both of which have good biocompatibility. 36,37 RES@PPD NPs are a new candidate drug for the treatment of periodontitis, and their cytocompatibility should be explored before clinical application. In this paper, the viability of L929 and RAW 264.7 at different concentrations of NPs was investigated using the CCK-8 assay.…”

Section: Biocompatibility Of Res@ppd Npsmentioning

confidence: 99%

Facile engineering of resveratrol nanoparticles loaded with 20(S)-protopanaxadiol for the treatment of periodontitis by regulating the macrophage phenotype

Huangfu

Zhang

et al. 2023

Nanoscale

View full text Add to dashboard Cite

show abstract

Advances in Ginsenosides

Abstract: Ginsenosides are unique to plants that belong to the Panax genus [...]

Cited by 15 publications

References 13 publications

Effects of combination therapy with Shenfu Injection in critically ill patients with septic shock receiving mechanical ventilation: A multicentric, real-world study

Effects of combination therapy with Shenfu Injection in critically ill patients with septic shock receiving mechanical ventilation: A multicentric, real-world study

Natural bioactive compounds as potential sources for alleviation and treatment of androgenetic alopecia: A research advance

Facile engineering of resveratrol nanoparticles loaded with 20(S)-protopanaxadiol for the treatment of periodontitis by regulating the macrophage phenotype

Contact Info

Product

Resources

About